SCHEMBL1669232

SCHEMBL1669232

CCCCOC(=O)N1CCNC(C)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GBA2 Q9HCG7 1/20 0.41
BIRC2 Q13490 1/20 0.40
ALDH1A1 P00352 2/20 0.38
HRH2 P25021 1/20 0.37
HRH1 P35367 1/20 0.37
ATM Q13315 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
HPGD P15428 3/20 0.35
TSHR P16473 1/20 0.34
GNAI3 P08754 3/20 0.34
GNAO1 P09471 3/20 0.34
GNAI1 P63096 3/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
BCHE P06276 1/20 0.34
CHRNB2 P17787 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29409415 1.00 POLB (0.51) POLBLMNASMN1; SMN2GBA2BIRC2
SCHEMBL27464999 1.00 POLB (0.51) POLBLMNASMN1; SMN2GBA2BIRC2
SCHEMBL18706112 0.91 BIRC2 (0.42) POLBLMNASMN1; SMN2GBA2BIRC2
SCHEMBL18705787 0.91 BIRC2 (0.42) POLBLMNASMN1; SMN2GBA2BIRC2
SCHEMBL18705785 0.91 BIRC2 (0.42) POLBLMNASMN1; SMN2GBA2BIRC2
SCHEMBL30578823 0.87 POLB (0.48) POLBLMNASMN1; SMN2GBA2ALDH1A1
SCHEMBL21296102 0.87 POLB (0.48) POLBLMNASMN1; SMN2GBA2ALDH1A1
Hydrochloric Acid SCHEMBL27854646 0.86 POLB (0.47) POLBLMNASMN1; SMN2GBA2ALDH1A1
SCHEMBL952240 0.85 BIRC2 (0.45) POLBLMNASMN1; SMN2BIRC2ALDH1A1
SCHEMBL956554 0.85 BIRC2 (0.45) POLBLMNASMN1; SMN2BIRC2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334303-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE Nurix Therapeutics, Inc. (US) 2024-03-13 EP disclosed
US-11866428-B2 Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (GB) 2024-01-09 US disclosed
WO-2023067354-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed
WO-2022235715-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 WO disclosed
WO-2022132997-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS ABBVIE INC. (US) 2022-06-23 WO disclosed
EP-3755703-A1 N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER Incyte Corporation (US) 2020-12-30 EP disclosed
US-10836759-B2 Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2020-11-17 US disclosed
US-20200055845-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2020-02-20 US disclosed
WO-2019164846-A1 N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER INCYTE CORPORATION (US) 2019-08-29 WO disclosed
EP-2489663-A1 Compounds as syk kinase inhibitors Almirall, S.A. (ES) 2012-08-22 EP disclosed
WO-2011140324-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
EP-2313096-A1 NEW COMPOUNDS V AstraZeneca AB (Publ) (SE) 2011-04-27 EP disclosed
US-20100249411-A1 Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines WU WENXUE 2010-09-30 US disclosed
US-7745626-B2 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines SCHERING CORPORATION (US) 2010-06-29 US disclosed
EP-2141143-A2 Stereoselective alkylation of chiral 2-methyl-4 protected piperazines SCHERING CORPORATION (US) 2010-01-06 EP disclosed
EP-2141153-A2 Stereoselective alkylation of chiral 2-methyl-4 protected piperazines SCHERING CORPORATION (US) 2010-01-06 EP disclosed
WO-2009147211-A1 NEW COMPOUNDS V BIOVITRUM AB (PUBL) (SE) 2009-12-10 WO disclosed
EP-1490346-B1 STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES SCHERING CORP (US) 2009-12-02 EP disclosed
US-7217447-B2 Ink-jet recording sheet FUJIFILM CORPORATION (JP) 2007-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836759-B2 Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer IDH1, IDH2, IDH3B POLB 3393/4885LMNA 2898/4885SMN1; SMN2 1955/4885
US-20100249411-A1 Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines ALKBH5, AZI2, PNMT POLB 1478/4885LMNA 3618/4885SMN1; SMN2 710/4885
US-11866428-B2 Bicyclic heterocycle compounds and their uses in therapy H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 POLB 237/4885LMNA 646/4885SMN1; SMN2 1240/4885
US-20200055845-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS POLB 813/4885LMNA 2606/4885SMN1; SMN2 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.